CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	9 Months Ended
	Sep. 30, 2022	Sep. 30, 2021
Cash flows from operating activities:
Net loss	$ (82,538)	$ (102,456)
Adjustments to reconcile net loss to net cash used in operating activities
Depreciation and amortization expense	1,354	339
Amortization of premiums and discount on short-term investments	100	0
Stock-based compensation expense	3,885	639
Non cash lease expense	6,992	2,910
Deferred income taxes	(762)	(1,867)
Loss on disposal of property and equipment	8	0
Change in fair value of preferred stock tranche right liability	0	74,319
Change in fair value of anti-dilution obligation	0	6,681
Change in fair value of related party short-term investment	6,419	(1,075)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets	(1,080)	(642)
Accounts payable	2,027	1,105
Accrued expenses and other current liabilities	(29,961)	1,896
Lease liabilities	(7,558)	(2,744)
Net cash used in operating activities	(101,114)	(20,895)
Cash flows from investing activities:
Purchases of property and equipment	(11,281)	(3,768)
Purchase of short-term investments	(89,464)	(81,841)
Matured short-term investments	68,000	0
Payments of security deposits	(664)	(171)
Net cash used in investing activities	(33,409)	(85,780)
Cash flows from financing activities:
Payments of deferred offering costs	(2,642)	0
Net proceeds from stock option exercises	63	0
Net cash (used in) provided by financing activities	(2,579)	270,364
Net (decrease) increase in cash, cash equivalents and restricted cash	(137,102)	163,689
Cash and cash equivalents at beginning of period	198,545	36,975
Cash and cash equivalents at end of period	61,443	200,664
Supplemental cash flow information:
Right-of-use assets obtained in exchange for new operating lease liabilities	28,590	10,103
Supplemental disclosure of non-cash investing and financing activities:
Settlement of anti-dilution obligation	0	7,536
Settlement of related party forward contract	12,020	0
Deferred offering costs included in accounts payable and accrued expenses at period end	239	0
Purchases of property and equipment included in accounts payable and accrued expenses at period end	870	0
Accretion of preferred stock to redemption value	0	1,468
Unrealized loss on short-term investments	454	9
Reconciliation of cash, cash equivalents and restricted cash:
Cash and cash equivalents	47,947	200,664
Restricted cash	13,496	0
Total cash, cash equivalents and restricted cash shown in the statement of cash flows	61,443	200,664
Series A Redeemable Convertible Preferred Stock
Cash flows from financing activities:
Proceeds from the issuance of convertible preferred stock	0	70,721
Supplemental disclosure of non-cash investing and financing activities:
Settlement of Series A preferred stock tranche obligation	0	91,834
Issuance of Series A preferred stock at a price below fair value	0	998
Series B Convertible Preferred Stock
Cash flows from financing activities:
Proceeds from the issuance of convertible preferred stock	$ 0	$ 199,643